From: Novel therapies in breast cancer: what is new from ASCO 2008
Agent | Target | Toxicity | Evaluation at ASCO |
---|---|---|---|
Lapatinib | EGFR/HER2 | Diarrhea, rash, nausea, vomiting | -monotherapy in inflammatory BC |
 |  |  | -c/w trastuzumab |
 |  |  | -c/w bevacizumab |
HKI-272 | Pan HER | Diarrhea, nausea | n/a |
Trastuzumab DM-1 | HER2 | Transaminitis, fatigue, thrombocytopenia, anemia, neuropathy | -monotherapy refractory to trastuzumab |
Pertuzumab | HER2 | Diarrhea, pain, nausea, vomiting, mucositis | -c/w trastuzumab |
Tanespimycin | HSP 90 | Fatigue, diarrhea, dizziness, headache | -c/w trastuzumab |
Cetuximab | EGFR | Rash, diarrhea, nausea, vomiting | -c/w carboplatin in triple negative BC |
 |  |  | -c/w irinotecan |
Bevacizumab | VEGF | Hypertension, proteinuria, bleeding, thromboembolism | -c/w lapatinib |
 |  |  | -c/w docetaxel |
 |  |  | -c/w nab-paclitaxel |
Gefitinib | EFGR | Rash, diarrhea, nausea, vomiting | -c/w anastrazole |
RAD001 | mTOR | Stomatitis, fatigue, anorexia, diarrhea, headache, rash | -c/w anastrazole |
 |  |  | -c/w paclitaxel and trastuzumab |
 |  |  | -c/w navelbine and trastuzumab |
Pazopanib | VEGFR, PDGFR, C-kit | Diarrhea, rash, nausea | -c/w lapatinib |
Sunitinib | VEGFR, PDGFR, C-kit | Mucositis, fatigue, nausea, diarrhea | n/a |
Axitinib | VEGFR 1,2, PDGFR, C-kit | Diarrhea, nausea, alopecia, stomatitis | n/a |
C1311 | Topoisomerase II | Neutropenia | -monotherapy in refractory BC |
Pemetrexed | Anti-folate | Myelosuppression, anemia | -1st line monotherapy in advanced BC |
Larotaxel | Cytotoxic | Neutropenia, fatigue | -c/w trastuzumab |
Orataxel | Cytotoxic | Neutropenia, fatigue, peripheral neuropathy | -monotherapy in taxane resistant BC |